Postmenopausal hormone Rx may cut risk for glaucoma

February 1, 2014
Postmenopausal hormone rx may cut risk for glaucoma

(HealthDay)—Use of estrogen-only postmenopausal hormone (PMH) treatment may help reduce the risk for primary open-angle glaucoma (POAG), according to research published online Jan. 30 in JAMA Ophthalmology.

Paula Anne Newman-Casey, M.D., from University of Michigan in Ann Arbor, and colleagues retrospectively reviewed claims data from 152,163 women 50 years or older enrolled in a U.S. managed-care plan for at least four years and with at least two visits to an eye care provider during the period 2001 through 2009. Outpatient pharmacy claims were used to identify use of PMH medications.

The researchers found that 1.9 percent of enrollees developed POAG. Each additional month of use of PMH containing estrogen only was associated with a 0.4 percent reduced risk for POAG (hazard ratio [HR], 0.996; P = 0.02), after adjustment for other confounding factors. Each additional month of use of estrogen + progesterone (HR, 0.994; P = 0.08) or + androgen (HR, 0.999; P = 0.89) did not affect risk for POAG.

"If prospective studies confirm the findings of this analysis, novel treatments for this sight-threatening condition may follow," the authors write.

Explore further: High estrogen levels plus diabetes may boost dementia risk

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

High estrogen levels plus diabetes may boost dementia risk

January 29, 2014
(HealthDay)—Older women with high levels of the hormone estrogen may be at a greater risk for dementia, especially if they also have diabetes, new research suggests.

VTE risk varies by hormone therapy formulation

September 18, 2012
(HealthDay)—The risk of venous thromboembolism (VTE) in postmenopausal women differs considerably according to the formulation of hormone therapy (HT) used, with the highest VTE risk seen in users of oral estrogen-progestin ...

Study links genes to common forms of glaucoma

April 26, 2012
Results from the largest genetic study of glaucoma, a leading cause of blindness and vision loss worldwide, showed that two genetic variations are associated with primary open angle glaucoma (POAG), a common form of the disease. ...

Long-term use of estrogen hormone therapy linked to higher risk for breast cancer

April 2, 2012
In a landmark study, researchers have linked the long-term use of estrogen plus progesterone and estrogen-only hormone therapy with a higher risk for developing breast cancer.

Recommended for you

Study advances gene therapy for glaucoma

January 16, 2018
While testing genes to treat glaucoma by reducing pressure inside the eye, University of Wisconsin-Madison scientists stumbled onto a problem: They had trouble getting efficient gene delivery to the cells that act like drains ...

New study offers added hope for patients awaiting corneal transplants

January 9, 2018
New national research led by Jonathan Lass of Case Western Reserve University School of Medicine has found that corneal donor tissue can be safely stored for 11 days before transplantation surgery to correct eye problems ...

Diabetic blindness caused and reversed "trapped" immune cells in rodent retinas

January 3, 2018
Johns Hopkins researchers have discovered a cell signaling pathway in mice that triggers vision loss in patients with diabetic retinopathy and retinal vein occlusion – diseases characterized by the closure of blood vessels ...

Ophthalmologists increasingly dissatisfied with electronic health records

December 29, 2017
Ophthalmologists' use of electronic health records (EHR) systems for storing and accessing patients' medical histories more than doubled between 2006 and 2016, while their perceptions of financial and clinical productivity ...

Higher omega-3 fatty acid intake tied to lower glaucoma risk

December 26, 2017
(HealthDay)—Increased daily intake of ω-3 fatty acids is associated with lower odds of glaucoma, but higher levels of total polyunsaturated fatty acid (PUFA) intake are associated with higher odds of developing glaucoma, ...

Protein analysis allows for treatment of eye-disease symptoms with existing drugs

December 21, 2017
Demonstrating the potential of precision health, a team led by a researcher at the Stanford University School of Medicine has matched existing drugs to errant proteins expressed by patients with a rare eye disease.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.